Litfulo (Ritlecitinib)

• Serious infections may occur in those receiving Ritlecitinib capsules. Precisely monitor patients for the establishment of signs and symptoms of infection during and after treatment. Interrupt dosing if a serious or opportunistic infection occurs.
• Screen individuals for tuberculosis (TB) prior to starting therapy. Ritlecitinib 50 mg should not be given to those with active TB. Anti-TB treatment needs to be started before starting therapy with Ritlecitinib in those with a new diagnosis of latent TB or previously untreated latent TB.
• Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster) may occur. If herpes zoster occurs, consider interrupting therapy until the resolution of episodes. Screening for viral hepatitis needs to be performed as per clinical guidelines prior to starting this therapy.
• Malignancies such as non-melanoma skin cancer (NMSC) may occur. The risks and benefits of Litfulo treatment need to be considered before starting or continuing therapy in those with a known malignancy other than fully treated NMSC or cervical cancer. Periodic skin assessment is required for those who are at higher risk for skin cancer. 
• An event of pulmonary embolism may occur in those receiving Litfulo treatment. Do not use this medicine in those who may be at higher risk of thrombosis. In case symptoms of embolism or thrombosis occur, patients should interrupt therapy with Litfulo 50 mg and be evaluated quickly and treated as required.
• Critical reactions including rash and anaphylactic reactions may occur in patients receiving Litfulo 50 mg capsules. In the occurrence of a clinically significant hypersensitivity reaction, interrupt therapy with Litfulo and institute apt treatment.
• Treatment with Litfulo capsules 50 mg may be responsible for decreasing lymphocytes as well as platelets. Prior to initiating treatment, perform ALC and platelet counts.

What documents are required to import LITFULO to India?

LITFULO (ritlecitinib) capsules can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients id proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

LITFULO (ritlecitinib capsules) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Litfulo in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of LITFULO (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Litfulo 50 mg price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the ACCRUFER (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Accrufer®?

Ferric Maltol is a Generic Name for the trade name drug Accrufer®.

What is the Manufacturer’s Name of Accrufer®?

Accrufer® is manufactured by Shield Therapeutics plc. 

Is Accrufer® approved by the FDA?

Yes, Accrufer® is approved by the FDA. Date of first/initial approval: July 25, 2019.

Where can I get Accrufer® at the best price in India?

To get the best Accrufer Capsules price in India, kindly get in touch with Indian Pharma Network (a WHO GDP & ISO 9001:2008 certified company). For Accrufer®, a valid medical prescription is required from a treating physician.

What is the dosage and form of Accrufer® supplied?

Accrufer® is supplied as Capsules: 30 mg for oral administration. 

What are the most common side effects of Accrufer®? 

The most common side effects of Accrufer® are constipation, flatulence, diarrhea, abdominal pain, feces discolored, nausea, vomiting, and abdominal discomfort/distension.

How much does Accrufer® cost in India?

The medicine Accrufer cost in India can vary. In order to procure this oral iron treatment legally, you can Call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Accrufer®?

Store the capsules of Accrufer at temperature of 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F).

Is it safe to buy Accrufer® online from India?

Yes, one can buy Accrufer from India at the best price from the Indian Pharma Network (IPN) if Accrufer is not registered or is unavailable in the respective country. We can facilitate the Import of Accrufer 30 mg capsules through legal channels.